Stay updated with breaking news from Markus Meyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A study challenges the dogma of beta-blockers for HF with preserved ejection fraction. For now, the strategy might only be for HFpEF patients already with pacemakers.
Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) ALE.F02 found to be well tolerated at all doses with a good safety profile and
The 250 MW Netzbooster (“Grid Booster”) project is being deployed to increase network utilisation across the German transmission system by using...
Fluence Energy GmbH (“Fluence”), a subsidiary of Fluence Energy, Inc. (NASDAQ: FLNC), a leading global provider of energy storage products and services, and
There has been a great deal of talk about precision farming over the past few years, yet the adoption of digital aids for the day-to-day management of